Novartis Ag (NVS) Non-Current Receivables (2017 - 2025)
Novartis Ag (NVS) has disclosed Non-Current Receivables for 9 consecutive years, with $403.0 million as the latest value for Q4 2025.
- Quarterly Non-Current Receivables rose 125.14% to $403.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $403.0 million through Dec 2025, up 125.14% year-over-year, with the annual reading at $403.0 million for FY2025, 125.14% up from the prior year.
- Non-Current Receivables hit $403.0 million in Q4 2025 for Novartis Ag, up from $179.0 million in the prior quarter.
- In the past five years, Non-Current Receivables ranged from a high of $403.0 million in Q4 2025 to a low of $179.0 million in Q4 2024.
- Historically, Non-Current Receivables has averaged $235.4 million across 5 years, with a median of $197.0 million in 2022.
- Biggest five-year swings in Non-Current Receivables: dropped 16.36% in 2024 and later skyrocketed 125.14% in 2025.
- Year by year, Non-Current Receivables stood at $184.0 million in 2021, then increased by 7.07% to $197.0 million in 2022, then rose by 8.63% to $214.0 million in 2023, then fell by 16.36% to $179.0 million in 2024, then surged by 125.14% to $403.0 million in 2025.
- Business Quant data shows Non-Current Receivables for NVS at $403.0 million in Q4 2025, $179.0 million in Q4 2024, and $214.0 million in Q4 2023.